Last reviewed · How we verify
F8IL10
At a glance
| Generic name | F8IL10 |
|---|---|
| Also known as | Dekavil |
| Sponsor | Philogen S.p.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis (PHASE1)
- Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment (PHASE1)
- A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX (PHASE2)
- Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F8IL10 CI brief — competitive landscape report
- F8IL10 updates RSS · CI watch RSS
- Philogen S.p.A. portfolio CI